ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease ...

Mistletoe therapy may improve the QOL of patients with cancer; however, evidence does not support a survival benefit, ...

The traditional gold standard of clinical trials with a randomized, placebo-controlled design involving hundreds of patients ...

A groundbreaking study in genetics education examines the relationship between the quality of genetics education and the ...

The more invasive segment 4b/5 resection did not improve overall or disease-free survival compared to wedge resection in gallbladder cancer. 2. Segment 4b/5 resection was associated with longer ...

BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) caused by carbapenem-resistant ...

A large randomized trial in Germany and Spain found that lowering milk protein intake during the second year of life did not ...

Elion Therapeutics, a biotechnology company dedicated to transforming the treatment of life-threatening fungal infections, today announced the initiation of its Phase 2 clinical trial evaluating ...

Objective The multinational ERYTHRO ( NCT06046534) study investigated the experience of patients with moderate-to-severe SLE ...

UAB is leading a national study examining how personalized genetic risk information can improve prevention of chronic ...